

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 August 2012 (16.08.2012)



(10) International Publication Number
WO 2012/107706 A8

- (51) International Patent Classification:
C07D 279/20 (2006.01) *A61P 25/00* (2006.01)
A61K 31/5415 (2006.01)
- (21) International Application Number:
PCT/GB2011/001221
- (22) International Filing Date:
15 August 2011 (15.08.2011)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
201101060-0 11 February 2011 (11.02.2011) SG
61/485,880 13 May 2011 (13.05.2011) US
- (71) Applicant (for all designated States except US): **WISTA LABORATORIES LTD.** [SG/SG]; 51 Ayer Rajah Crescent, #07-01/02, Singapore 139948 (SG).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **MARSHALL, Colin** [GB/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen AB24 3UE, Scotland (GB). **CLUNAS, Scott** [GB/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen AB24 3UE, Scotland (GB). **STOREY, John, Mervyn, David** [GB/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen AB24 3UE, Scotland (GB). **SINCLAIR, James, Peter** [GB/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen AB24 3UE, Scotland (GB). **BADDELEY, Thomas, Craven** [GB/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen AB24 3UE, Scotland (GB). **ISHAQ, Ahtsham** [GB/GB]; WisTa


Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen AB24 3UE, Scotland (GB). **SIMPSON, Michael** [GB/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen AB24 3UE, Scotland (GB). **WILLIAMSON, Craig** [GB/GB]; ID Business Solutions Ltd., 2 Occam Court, Surrey Research Park, Guildford, Surrey, GU2 7QB (GB). **WOOD, Barry, Alan** [GB/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen AB24 3UE, Scotland (GB). **WISCHIK, Claude, Michel** [FR/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen AB24 3UE, Scotland (GB). **HARRINGTON, Charles, Robert** [GB/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen AB24 3UE, Scotland (GB). **RICKARD, Janet, Elizabeth** [GB/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen AB24 3UE, Scotland (GB). **HORSLEY, David** [GB/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen AB24 3UE, Scotland (GB). **LOH, Yin, Sze** [SG/SG]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen AB24 3UE, Scotland (SG). **KHAN, Karrar, Ahmad** [GB/GB]; WisTa Laboratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen AB24 3UE, Scotland (GB).

(74) Agents: **KREMER, Simon, M.** et al.; Mewburn Ellis LLP, 33 Gutter Lane, London EC2V 8AS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,

[Continued on next page]

(54) Title: PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE



(57) Abstract: The invention relates to compounds of general formula (I): wherein: each of R^1 and R^9 is independently selected from: -H, C_{1-4} alkyl, C_{2-4} alkenyl, and halogenated C_{1-4} alkyl; each of R^{3NA} and R^{3NB} is independently selected from: -H, C_{1-4} alkyl, C_{2-4} alkenyl, and halogenated C_{1-4} alkyl; each of R^{7NA} and R^{7NB} is independently selected from: -H, C_{1-4} alkyl, C_{2-4} alkenyl, and halogenated C_{1-4} alkyl; and wherein: each of R^A and R^B is independently selected from: C_{1-4} alkyl, halogenated C_{1-4} alkyl, and C_{6-10} aryl; or R^A and R^B are linked to form a group selected from: C_{1-6} alkylene and C_{6-10} arylene; and pharmaceutically acceptable salts thereof, which are useful in the treatment of, for example, Alzheimer's disease. In other aspects the invention also relates to novel formulations of 3,7-diamino-10H-phenothiazinium salts.



KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*
- *as to non-prejudicial disclosures or exceptions to lack of novelty (Rule 4.17(v))*

Published:

- *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

19 September 2013

(15) Information about Correction:

see Notice of 19 September 2013